Overview

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Status:
Not yet recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics (according to 2017 ELN criteria)

Phase:

Phase 2

Details

Lead Sponsor:

Centre Hospitalier Universitaire de Nice

Collaborators:

Acute Leukemia French Association
Jazz Pharmaceuticals

Treatments:

Cytarabine
Idarubicin